NVSEF News and Press, Novartis Ag Basel Akt From 10/24/23

2023-10-24 11:23:00 ET Summary Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits a...

2023-10-24 11:09:02 ET Novartis AG. (NVS) Shareholder Analyst Call October 24, 2023, 07:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Shreeram Aradhye - Global Head of Development & Chief Medical Officer for Novartis Jeff Legos - ...

2023-10-10 14:10:30 ET Summary Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside. The company's radiopharmaceutical technology could revolutionize the cance...

2023-10-06 18:09:48 ET Summary The biotechnology and pharmaceutical sectors have been under pressure in 2023, with the Invesco Pharmaceuticals ETF down 9% and the iShares Biotechnology ETF down 6%. Elevated interest rates and potential pricing power erosion are the primary headwin...

2023-10-06 00:48:06 ET Summary Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started trading with a market cap of $11.2 billion. The com...

2023-10-04 10:26:12 ET More on Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis said to be considering a partial sale o...

2023-10-03 10:23:02 ET More on Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis readies Sandoz spinoff for trading on O...

2023-09-25 12:25:28 ET More on Novartis Seeking Alpha’s Quant Rating on Novartis Historical earnings data for Novartis Dividend scorecard for Novartis Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expan...

2023-09-22 14:48:41 ET Summary Dimensional International Value ETF is an actively managed fund picking value stocks in developed countries except the U.S. It is overweight in financials, but it is well diversified across countries and holdings. Valuation ratios, growth metrics...

2023-09-19 06:58:00 ET More on BeiGene, Novartis, etc. Sales Success Comes With Side Effects For Drug Maker BeiGene Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis shareholders approve 100...